Patients must be deemed able to comply with the treatment plan and follow-up schedule
Patients who are able to comply with the protocol follow-up schedule
Patients must be deemed able to comply with the treatment plan and follow-up schedule
Must be able to comply with the treatment plan and follow-up schedule
Patients who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
Willingness to give consent and comply with all study-related evaluations and treatment schedule; and
Ability to comply with the treatment schedule
Patients who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
Ability and willingness to obtain all required scans per study schedule
Any other condition (e.g. psychiatric disorder) that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the study requirements or visit schedule
Able to comply with the treatment schedule
Willing to comply with proposed visit and treatment schedule
Ability to comply with the treatment schedule
Able to comply with the treatment schedule
Patient is unable or unwilling to provide written informed consent or comply with follow-up schedule
Willingness to follow the requirements of the intravenous ascorbic acid program schedule
Inability to give consent or adhere to follow-up schedule
Willing and able to comply with follow-up schedule
Clinical history, current alcohol (ethanol), or illicit drug use which, in the judgment of the investigator, will interfere with the subject's ability to comply with the dosing schedule and protocol-specified evaluations.
Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
Willing and able to give written informed consent and comply with study visit schedule
Patients must comply with the treatment plan and follow-up schedule.
Willing and able to give written informed consent and comply with study visit schedule.
Willingness to follow study visit schedule, pregnancy precautions and other protocol requirements.
Unable to comply with lab appointments schedule and PRO assessments
Willing to schedule definitive resection of DCIS 2-5 weeks after study enrollment
Inability to provide informed consent or to comply with the schedule of office and treatment visits
Able to comply with the treatment schedule
Unable to comply with the study follow-up schedule
Subjects unable or unwilling to comply with the study visit schedule and requirements of the study
Willing to give consent and comply with study-related evaluation and treatment schedule; and
Willing and able to comply with post-operative treatment protocol and follow-up visit schedule.
Able to comply with study visit schedule and assessments.
Patient is unwilling or unable to comply with the follow-up schedule
Must be able and willing to comply with the study visit schedule and study procedures.
Unable to commit to intervention schedule (6 weekly group meetings)
Chemotherapy treatment schedule < 12 weeks
Able to commit to a long term follow-up schedule
Patients must be deemed able to comply with the treatment plan and follow-up schedule
Unwilling or unable to comply with the follow-up schedule
Cannot commit to the intervention schedule
Willing and able to schedule mastectomy 4 weeks (+/- 7days) following start of study agent
Subjects unable or unwilling to comply with the study visit schedule and requirements of the study
Inability to commit to the intervention schedule
Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol
Patient is not likely to comply with the follow-up evaluation schedule
Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol
Patient is not likely to comply with the follow-up evaluation schedule
